EvaHong

Associate

Hong Kong + 852.2526.6895

Eva Hong's practice focuses on corporate finance, private equity, and general corporate matters. She advises clients on initial public offerings on the Main Board of the Hong Kong Stock Exchange, ongoing compliance matters of PRC-based Hong Kong-listed companies, and fund formation matters.

Prior to joining Jones Day, Eva interned at several international law firms where she gained experience in debt capital markets, dispute resolution, and intellectual property.

Experience


  • AGIC Capital closes $1.2 billion fund for investments in smart industriesJones Day acted as fund formation counsel to AGIC Capital for its $1.2 billion final closing of its second fund, AGIC Fund II L.P., which will be focused on advanced industrial and medical technology investments.
  • Shanghai Junshi Biosciences completes $329 million placing of new H Shares on main board of The Stock Exchange of Hong Kong LimitedJones Day advised Shanghai Junshi Biosciences Co., Ltd. (the “Company”), a company listed on the main board of The Stock Exchange of Hong Kong Limited and the STAR Market of the Shanghai Stock Exchange, in connection with its US$329 million placing of new H Shares of the Company.
  • STERIS acquires Cantel Medical for $3.6 billionJones Day advised STERIS plc in its acquisition of Cantel Medical Corp, a global provider of infection prevention products and services primarily to endoscopy and dental customers, for $3.6 billion.
  • CLSA Capital, CLSA, CCB International Capital, and China Galaxy complete approximate $210 million IPO on The Stock Exchange of Hong Kong Limited by Luzhou BankJones Day acted as counsel for the sole sponsor, CLSA Capital Markets Limited, and underwriters, comprising of CLSA Limited, CCB International Capital Limited, China Galaxy International Securities (Hong Kong) Co., Limited, and others, in connection with the $210 million initial public offering of H shares on The Stock Exchange of Hong Kong Limited by Luzhou Bank Co., Ltd. and concurrent Regulation S offering.
  • Shanghai Junshi Biosciences completes $450 million IPO on The Stock Exchange of Hong Kong LimitedJones Day acted as Hong Kong and U.S. counsel for Shanghai Junshi Biosciences Co., Ltd. in connection with its over $450 million initial public offering on The Stock Exchange of Hong Kong Limited and concurrent Rule 144A and Regulation S offerings.